Results from a Phase 2b, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122/DNL151 in Participants with Early-Stage Parkinson's Disease (MDS Congress 2026) - Sep 19, 2026 - Abstract #LBA 19; Pres time: Oct 7, 2026; 12:30 PM - 01:30 PM; Location: Conference Room E3, 3rd Floor; P2 | "648 participants were randomized and dosed. Baseline demographics and disease characteristics were generally balanced between treatment groups. BIIB122/DNL151 did not demonstrate a statistically significant benefit on the primary endpoint compared to placebo, with hazard ratio=1.04 (95% CI, 0.85, 1.28), p=0.4538, and did not show benefit on secondary endpoints compared to placebo."
Clinical • Late-breaking abstract • P2b data • CNS Disorders • Movement Disorders • Parkinson's Disease • LRRK2
|
|
R. Llorens Arenas; A. Siderowf; A. Lang; M. Yang; O. Mabrouk; C. Paisan-Ruiz; B. Hersh; D. Jennings; S. Huntwork-Rodriguez; J. Kluss; R. Maciuca; P. Roychowdhury; S. Dhuria; P. Wang; K. Harrison; J. Goldman; G. Curiale; M. Wald; D. Graham; M. King; R. Hauser
|